Integra LifeSciences (NASDAQ:IART – Get Free Report) had its target price raised by Truist Financial from $25.00 to $32.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “hold” rating on the life sciences company’s stock. Truist Financial’s target price indicates a potential upside of 1.11% from the company’s current price.
A number of other brokerages have also issued reports on IART. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Wells Fargo & Company cut Integra LifeSciences from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $45.00 to $25.00 in a research note on Tuesday, May 7th. Citigroup boosted their price target on shares of Integra LifeSciences from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 10th. Bank of America reduced their price objective on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research report on Tuesday, May 7th. Finally, JMP Securities lowered their price objective on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating on the stock in a research note on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $32.86.
Read Our Latest Analysis on Integra LifeSciences
Integra LifeSciences Stock Performance
Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. The company had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period last year, the company earned $0.74 earnings per share. On average, analysts predict that Integra LifeSciences will post 3.03 earnings per share for the current year.
Insider Activity
In other Integra LifeSciences news, Chairman Stuart Essig purchased 52,641 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were purchased at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the completion of the transaction, the chairman now owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.10% of the company’s stock.
Institutional Trading of Integra LifeSciences
Several institutional investors have recently made changes to their positions in IART. Capital Research Global Investors lifted its position in Integra LifeSciences by 37.7% in the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after buying an additional 1,621,655 shares in the last quarter. Norges Bank purchased a new stake in shares of Integra LifeSciences during the fourth quarter worth $29,272,000. Boston Partners acquired a new stake in Integra LifeSciences during the first quarter valued at $19,383,000. Point72 Europe London LLP grew its stake in Integra LifeSciences by 54.9% in the fourth quarter. Point72 Europe London LLP now owns 719,663 shares of the life sciences company’s stock valued at $31,341,000 after purchasing an additional 255,201 shares in the last quarter. Finally, Champlain Investment Partners LLC increased its position in Integra LifeSciences by 10.3% in the 1st quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after purchasing an additional 252,015 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Read More
- Five stocks we like better than Integra LifeSciences
- Find and Profitably Trade Stocks at 52-Week Lows
- Real Estate Stock Signals a Boom in Manufacturing Activity
- Low PE Growth Stocks: Unlocking Investment Opportunities
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- The Significance of Brokerage Rankings in Stock Selection
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.